Pilot randomized trial of intermittent theta-burst stimulation versus H-Coil transcranial magnetic stimulation for treatment-resistant depression.

Psychiatry ResJun 11, 2026 (epub)
Clinical ResearchPsychiatry

Véronique Desbeaumes Jodoin, Emma Bousseau, François Trottier-Duclos et al.

✦ AI-curated · Sources linked

In 30 seconds

This pilot randomized trial compared the effectiveness of intermittent theta-burst stimulation (iTBS) and H-Coil transcranial magnetic stimulation (rTMS) in 28 adults with treatment-resistant depression (TRD). After six weeks, there were no significant differences in Hamilton Depression Rating Scale scores between the two groups (mean difference -0.40, 95% CI -5.23 to 4.43; p=.865).

Key findings

  • Adjusted week-6 HRSD-17 scores did not differ between iTBS and rTMS groups (mean difference -0.40).
  • Response rates were 40.0% for iTBS and 50.0% for rTMS (p>.60).
  • Remission rates were identical across groups at 20.0%.
  • Exploratory analyses suggested remitters had higher baseline executive functioning.

Why it matters

Understanding the comparative effectiveness of different stimulation techniques for treatment-resistant depression is crucial for optimizing patient outcomes. This study provides preliminary insights that could guide future research and treatment strategies.

Source

PubMed · PMID 42302659

Published in Psychiatry Res. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Psychiatry

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.